RWE’s willingness to change tack in light of new market dynamics and its buyback seem good news for its shares, analysts at ...

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression ...